{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["NSAID", "inflammation", "nonsteroidal anti-inflammatory drugs", "prostate cancer"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38001694", "DateRevised": {"Year": "2023", "Month": "11", "Day": "27"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "11", "Day": "16"}], "Language": ["eng"], "ELocationID": ["5435", "10.3390/cancers15225435"], "Journal": {"ISSN": "2072-6694", "JournalIssue": {"Volume": "15", "Issue": "22", "PubDate": {"Year": "2023", "Month": "Nov", "Day": "16"}}, "Title": "Cancers", "ISOAbbreviation": "Cancers (Basel)"}, "ArticleTitle": "The Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer.", "Abstract": {"AbstractText": ["Prostate cancer (PC) is the second most common type of cancer and the leading cause of death among men worldwide. Preventing the progression of cancer after treatments such as radical prostatectomy, radiation therapy, and hormone therapy is a major concern faced by prostate cancer patients. Inflammation, which can be caused by various factors such as infections, the microbiome, obesity and a high-fat diet, is considered to be the main cause of PC. Inflammatory cells are believed to play a crucial role in tumor progression. Therefore, nonsteroidal anti-inflammatory drugs along with their effects on the treatment of inflammation-related diseases, can prevent cancer and its progression by suppressing various inflammatory pathways. Recent evidence shows that nonsteroidal anti-inflammatory drugs are effective in the prevention and treatment of prostate cancer. In this review, we discuss the different pathways through which these drugs exert their potential preventive and therapeutic effects on prostate cancer."]}, "AuthorList": [{"Identifier": ["0000-0002-7549-8793"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}, {"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}], "LastName": "Maghsoudi", "ForeName": "Hossein", "Initials": "H"}, {"Identifier": ["0000-0002-3992-0088"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}, {"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}], "LastName": "Sheikhnia", "ForeName": "Farhad", "Initials": "F"}, {"Identifier": ["0000-0001-5495-3550"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biology, Medical University of Lodz, 90-151 Lodz, Poland."}], "LastName": "Sitarek", "ForeName": "Przemys\u0142aw", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, School of Medicine, Babol University of Medical Sciences, Babol 47176-47754, Iran."}], "LastName": "Hajmalek", "ForeName": "Nooshin", "Initials": "N"}, {"Identifier": ["0009-0000-9291-881X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}], "LastName": "Hassani", "ForeName": "Sepideh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}], "LastName": "Rashidi", "ForeName": "Vahid", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Kinesiology and Health Science, York University, Toronto, ON M3J 1P3, Canada."}], "LastName": "Khodagholi", "ForeName": "Sadaf", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Metabolic Disorders Research Center, Department of Biochemistry and Biophysics, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, Gorgan 49189-36316, Iran."}], "LastName": "Mir", "ForeName": "Seyed Mostafa", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}, {"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}], "LastName": "Malekinejad", "ForeName": "Faezeh", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}, {"Identifier": [], "Affiliation": "Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}, {"Identifier": [], "Affiliation": "Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}], "LastName": "Kheradmand", "ForeName": "Fatemeh", "Initials": "F"}, {"Identifier": ["0000-0002-4790-2701"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Plants, Faculty of Agriculture and Natural Resources, Arak University, Arak 38156-88349, Iran."}], "LastName": "Ghorbanpour", "ForeName": "Mansour", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia 57147-83734, Iran."}], "LastName": "Ghasemzadeh", "ForeName": "Navid", "Initials": "N"}, {"Identifier": ["0000-0002-4559-5015"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-237 Lodz, Poland."}], "LastName": "Kowalczyk", "ForeName": "Tomasz", "Initials": "T"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Cancers (Basel)", "NlmUniqueID": "101526829", "ISSNLinking": "2072-6694"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Siegel R., Miller K., Jemal A. Cancer statistics. 2020 CA Cancer J. Clin. Am. Cancer Soc. 2020;70:7\u201330.", "ArticleIdList": ["31912902"]}, {"Citation": "Virtanen V., Paunu K., Ahlskog J.K., Varnai R., Sipeky C., Sundvall M. PARP inhibitors in prostate cancer\u2013the preclinical rationale and current clinical development. Genes. 2019;10:565. doi: 10.3390/genes10080565.", "ArticleIdList": ["10.3390/genes10080565", "PMC6723995", "31357527"]}, {"Citation": "Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F., Bsc M.F.B., Me J.F., Soerjomataram M.I., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Giri V.N., Beebe-Dimmer J.L., editors. Familial Prostate Cancer. Seminars in Oncology. Elsevier; Amsterdam, The Netherlands: 2016.", "ArticleIdList": ["PMC6986340", "27899188"]}, {"Citation": "De Carlo F., Celestino F., Verri C., Masedu F., Liberati E., Di Stasi S.M. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: Surgical, oncological, and functional outcomes: A systematic review. Urol. Int. 2014;93:373\u2013383. doi: 10.1159/000366008.", "ArticleIdList": ["10.1159/000366008", "25277444"]}, {"Citation": "Amin N.P., Sher D.J., Konski A.A. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Appl. Health Econ. Health Policy. 2014;12:391\u2013408. doi: 10.1007/s40258-014-0106-9.", "ArticleIdList": ["10.1007/s40258-014-0106-9", "25022451"]}, {"Citation": "Mitsuzuka K., Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int. J. Urol. 2018;25:45\u201353. doi: 10.1111/iju.13473.", "ArticleIdList": ["10.1111/iju.13473", "29052905"]}, {"Citation": "De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gr\u00f6nberg H., Drake C.G., Nakai Y., Isaacs W.B., Nelson W.G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer. 2007;7:256\u2013269. doi: 10.1038/nrc2090.", "ArticleIdList": ["10.1038/nrc2090", "PMC3552388", "17384581"]}, {"Citation": "Nakai Y., Nonomura N. Inflammation and prostate carcinogenesis. Int. J. Urol. 2013;20:150\u2013160. doi: 10.1111/j.1442-2042.2012.03101.x.", "ArticleIdList": ["10.1111/j.1442-2042.2012.03101.x", "22852773"]}, {"Citation": "Taverna G., Pedretti E., Di Caro G., Borroni E.M., Marchesi F., Grizzi F. Inflammation and prostate cancer: Friends or foe? Inflamm. Res. 2015;64:275\u2013286. doi: 10.1007/s00011-015-0812-2.", "ArticleIdList": ["10.1007/s00011-015-0812-2", "25788425"]}, {"Citation": "Schillaci O., Scimeca M., Trivigno D., Chiaravalloti A., Facchetti S., Anemona L., Bonfiglio R., Santeusanio G., Tancredi V., Bonanno E., et al. Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. Nucl. Med. Biol. 2019;68:66\u201379. doi: 10.1016/j.nucmedbio.2019.01.003.", "ArticleIdList": ["10.1016/j.nucmedbio.2019.01.003", "30770226"]}, {"Citation": "Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357:539\u2013545. doi: 10.1016/S0140-6736(00)04046-0.", "ArticleIdList": ["10.1016/S0140-6736(00)04046-0", "11229684"]}, {"Citation": "Koul H., Kumar B., Koul S., Deb A., Hwa J., Maroni P., van Bokhoven A., Lucia M., Kim F., Meacham R. The role of inflammation and infection in prostate cancer: Importance in prevention, diagnosis and treatment. Drugs Today. 2010;46:929\u2013943. doi: 10.1358/dot.2010.46.12.1537942.", "ArticleIdList": ["10.1358/dot.2010.46.12.1537942", "21589950"]}, {"Citation": "Sfanos K.S., Yegnasubramanian S., Nelson W.G., De Marzo A.M. The inflammatory microenvironment and microbiome in prostate cancer development. Nat. Rev. Urol. 2018;15:11\u201324. doi: 10.1038/nrurol.2017.167.", "ArticleIdList": ["10.1038/nrurol.2017.167", "29089606"]}, {"Citation": "Fujita K., Hayashi T., Matsushita M., Uemura M., Nonomura N. Obesity, inflammation, and prostate cancer. J. Clin. Med. 2019;8:201. doi: 10.3390/jcm8020201.", "ArticleIdList": ["10.3390/jcm8020201", "PMC6406330", "30736371"]}, {"Citation": "Narita S., Nara T., Sato H., Koizumi A., Huang M., Inoue T., Habuchi T. Research evidence on high-fat diet-induced prostate cancer development and progression. J. Clin. Med. 2019;8:597. doi: 10.3390/jcm8050597.", "ArticleIdList": ["10.3390/jcm8050597", "PMC6572108", "31052319"]}, {"Citation": "Kashfi K. Anti-inflammatory agents as cancer therapeutics. Adv. Pharmacol. 2009;57:31\u201389.", "ArticleIdList": ["20230759"]}, {"Citation": "Zhang Z., Chen F., Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag. Res. 2018;10:4631. doi: 10.2147/CMAR.S175212.", "ArticleIdList": ["10.2147/CMAR.S175212", "PMC6197827", "30410398"]}, {"Citation": "Choe K.S., Cowan J.E., Chan J.M., Carroll P.R., D\u2019Amico A.V., Liauw S.L. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J. Clin. Oncol. 2012;30:3540. doi: 10.1200/JCO.2011.41.0308.", "ArticleIdList": ["10.1200/JCO.2011.41.0308", "PMC3454771", "22927523"]}, {"Citation": "Cardwell C.R., Flahavan E.M., Hughes C.M., Coleman H.G., O\u2019sullivan J.M., Powe D.G., Murray L.J. Low-dose aspirin and survival in men with prostate cancer: A study using the UK Clinical Practice Research Datalink. Cancer Causes Control. 2014;25:33\u201343. doi: 10.1007/s10552-013-0306-x.", "ArticleIdList": ["10.1007/s10552-013-0306-x", "24310109"]}, {"Citation": "Flahavan E., Bennett K., Sharp L., Barron T. A cohort study investigating aspirin use and survival in men with prostate cancer. Ann. Oncol. 2014;25:154\u2013159. doi: 10.1093/annonc/mdt428.", "ArticleIdList": ["10.1093/annonc/mdt428", "24356627"]}, {"Citation": "Ashok V., Dash C., Rohan T.E., Sprafka J.M., Terry P.D. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast. 2011;20:66\u201370. doi: 10.1016/j.breast.2010.07.004.", "ArticleIdList": ["10.1016/j.breast.2010.07.004", "20724158"]}, {"Citation": "Ghlichloo I., Gerriets V. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) StatPearls Publishing; Treasure Island, FL, USA: 2019."}, {"Citation": "Di Bella S., Luzzati R., Principe L., Zerbato V., Meroni E., Giuffr\u00e8 M., Croc\u00e8 L.S., Merlo M., Perotto M., Dolso E., et al. Aspirin and Infection: A Narrative Review. Biomedicines. 2022;10:263. doi: 10.3390/biomedicines10020263.", "ArticleIdList": ["10.3390/biomedicines10020263", "PMC8868581", "35203473"]}, {"Citation": "Menter D.G., Bresalier R.S. An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention. Annu. Rev. Pharmacol. Toxicol. 2022;63:165\u2013186. doi: 10.1146/annurev-pharmtox-052020-023107.", "ArticleIdList": ["10.1146/annurev-pharmtox-052020-023107", "36202092"]}, {"Citation": "Malkowski M.G. Encyclopedia of Inorganic and Bioinorganic Chemistry. John Wiley & Sons, Ltd.; Hoboken, NJ, USA: 2011. The Cyclooxygenases; pp. 1\u201318."}, {"Citation": "Kirschenbaum A., Klausner A.P., Lee R., Unger P., Yao S., Liu X.H., Levine A.C. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000;56:671\u2013676. doi: 10.1016/S0090-4295(00)00674-9.", "ArticleIdList": ["10.1016/S0090-4295(00)00674-9", "11018637"]}, {"Citation": "Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE 2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30:377\u2013386. doi: 10.1093/carcin/bgp014.", "ArticleIdList": ["10.1093/carcin/bgp014", "19136477"]}, {"Citation": "Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68:165\u2013175. doi: 10.1016/S0090-6980(02)00029-1.", "ArticleIdList": ["10.1016/S0090-6980(02)00029-1", "12432916"]}, {"Citation": "Lucotti S., Cerutti C., Soyer M., Gil-Bernab\u00e9 A.M., Gomes A.L., Allen P.D., Smart S., Markelc B., Watson K., Armstrong P.C., et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A 2. J. Clin. Investig. 2019;129:1845\u20131862. doi: 10.1172/JCI121985.", "ArticleIdList": ["10.1172/JCI121985", "PMC6486338", "30907747"]}, {"Citation": "Fujita H., Koshida K., Keller E.T., Takahashi Y., Yoshimito T., Namiki M., Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. Prostate. 2002;53:232\u2013240. doi: 10.1002/pros.10152.", "ArticleIdList": ["10.1002/pros.10152", "12386924"]}, {"Citation": "Bilani N., Bahmad H., Abou-Kheir W. Prostate cancer and aspirin use: Synopsis of the proposed molecular mechanisms. Front. Pharmacol. 2017;8:145. doi: 10.3389/fphar.2017.00145.", "ArticleIdList": ["10.3389/fphar.2017.00145", "PMC5359278", "28377721"]}, {"Citation": "Rauzi F., Kirkby N.S., Edin M.L., Whiteford J., Zeldin D.C., Mitchell J.A., Warner T.D. Aspirin inhibits the production of proangiogenic 15 (S)-HETE by platelet cyclooxygenase-1. FASEB J. 2016;30:4256\u20134266. doi: 10.1096/fj.201600530R.", "ArticleIdList": ["10.1096/fj.201600530R", "PMC5102123", "27633788"]}, {"Citation": "Kashiwagi E., Shiota M., Yokomizo A., Itsumi M., Inokuchi J., Uchiumi T., Naito S. Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. Endocr. Relat. Cancer. 2013;20:431\u2013441. doi: 10.1530/ERC-12-0344.", "ArticleIdList": ["10.1530/ERC-12-0344", "23493387"]}, {"Citation": "Olivan M., Rigau M., Col\u00e1s E., Garcia M., Montes M., Sequeiros T., Regis L., Celma A., Planas J., Placer J., et al. Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines. BioMed Res. Int. 2015;2015:762178. doi: 10.1155/2015/762178.", "ArticleIdList": ["10.1155/2015/762178", "PMC4306438", "25649906"]}, {"Citation": "Shiff S.J., Koutsos M.I., Qiao L., Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp. Cell Res. 1996;222:179\u2013188. doi: 10.1006/excr.1996.0023.", "ArticleIdList": ["10.1006/excr.1996.0023", "8549662"]}, {"Citation": "Kalinski P. Regulation of immune responses by prostaglandin E2. J. Immunol. 2012;188:21\u201328. doi: 10.4049/jimmunol.1101029.", "ArticleIdList": ["10.4049/jimmunol.1101029", "PMC3249979", "22187483"]}, {"Citation": "Sutmuller R., Garritsen A., Adema G.J. Regulatory T cells and toll-like receptors: Regulating the regulators. Ann. Rheum. Dis. 2007;66((Suppl. S3)):iii91\u2013iii95. doi: 10.1136/ard.2007.078535.", "ArticleIdList": ["10.1136/ard.2007.078535", "PMC2095279", "17934105"]}, {"Citation": "Hurwitz L.M., Kulac I., Gumuskaya B., Valle J.A.B.D., Benedetti I., Pan F., Liu J.O., Marrone M.T., Arnold K.B., Goodman P.J., et al. Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention TrialAspirin and Statin Use and Intraprostatic Inflammation. Cancer Prev. Res. 2020;13:853\u2013862. doi: 10.1158/1940-6207.CAPR-19-0450.", "ArticleIdList": ["10.1158/1940-6207.CAPR-19-0450", "PMC7541466", "32581009"]}, {"Citation": "Sharma S., Yang S.C., Zhu L., Reckamp K., Gardner B., Baratelli F., Huang M., Batra R.K., Dubinett S.M. Tumor cyclooxygenase-2/prostaglandin E2\u2013dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005;65:5211\u20135220. doi: 10.1158/0008-5472.CAN-05-0141.", "ArticleIdList": ["10.1158/0008-5472.CAN-05-0141", "15958566"]}, {"Citation": "Hurwitz L.M., Joshu C.E., Barber J.R., Prizment A.E., Vitolins M.Z., Jones M.R., Folsom A.R., Han M., Platz E.A. Aspirin and Non-Aspirin NSAID Use and Prostate Cancer Incidence, Mortality, and Case Fatality in the Atherosclerosis Risk in Communities StudyAspirin and Prostate Cancer Incidence and Mortality. Cancer Epidemiol. Biomark. Prev. 2019;8:563\u2013569. doi: 10.1158/1055-9965.EPI-18-0965.", "ArticleIdList": ["10.1158/1055-9965.EPI-18-0965", "PMC6401240", "30487131"]}, {"Citation": "Downer M.K., Allard C.B., Preston M.A., Gaziano J.M., Stampfer M.J., Mucci L.A., Batista J.L. Regular aspirin use and the risk of lethal prostate cancer in the physicians\u2019 health study. Eur. Urol. 2017;72:821\u2013827. doi: 10.1016/j.eururo.2017.01.044.", "ArticleIdList": ["10.1016/j.eururo.2017.01.044", "28189429"]}, {"Citation": "Bushra R., Aslam N. An overview of clinical pharmacology of ibuprofen. Oman Med. J. 2010;25:155. doi: 10.5001/omj.2010.49.", "ArticleIdList": ["10.5001/omj.2010.49", "PMC3191627", "22043330"]}, {"Citation": "Raegg C., Dormond O. Suppression of tumor angiogenesis by nonsteroidal anti-inflammatory drugs: A new function for old drugs. Sci. World J. 2001;1:808\u2013811. doi: 10.1100/tsw.2001.396.", "ArticleIdList": ["10.1100/tsw.2001.396", "PMC6084148", "12805715"]}, {"Citation": "Andrews J., Djakiew D., Krygier S., Andrews P. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother. Pharmacol. 2002;50:277\u2013284. doi: 10.1007/s00280-002-0485-8.", "ArticleIdList": ["10.1007/s00280-002-0485-8", "12357301"]}, {"Citation": "Arisan E.D., Akar R.O., Rencuzogullari O., Yerlikaya P.O., Gurkan A.C., Ak\u0131n B., Dener E., Kayhan E., Unsal N.P. The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells. Prostate Int. 2019;7:156\u2013165. doi: 10.1016/j.prnil.2019.09.003.", "ArticleIdList": ["10.1016/j.prnil.2019.09.003", "PMC6962753", "31970141"]}, {"Citation": "Wynne S., Djakiew D. NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 induction via the p38 MAPK-p75NTR pathway. Mol. Cancer Res. 2010;8:1656\u20131664. doi: 10.1158/1541-7786.MCR-10-0342.", "ArticleIdList": ["10.1158/1541-7786.MCR-10-0342", "PMC3003770", "21097678"]}, {"Citation": "Palayoor S., Youmell M., Calderwood S., Coleman C., Price B. Constitutive activation of I\u03baB kinase \u03b1 and NF-\u03baB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999;18:7389\u20137394. doi: 10.1038/sj.onc.1203160.", "ArticleIdList": ["10.1038/sj.onc.1203160", "10602496"]}, {"Citation": "Gavrilov V., Steiner M., Shany S. The combined treatment of 1, 25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer. Res. 2005;25:3425\u20133429.", "ArticleIdList": ["16101159"]}, {"Citation": "Kim M.H., Chung J. Synergistic cell death by EGCG and ibuprofen in DU-145 prostate cancer cell line. Anticancer. Res. 2007;27:3947\u20133956.", "ArticleIdList": ["18225555"]}, {"Citation": "Guma A., Akhtar S., Najafzadeh M., Isreb M., Baumgartner A., Anderson D. Ex vivo/in vitro effects of aspirin and ibuprofen, bulk and nano forms, in peripheral lymphocytes of prostate cancer patients and healthy individuals. Mutat. Res./Genet. Toxicol. Environ. Mutagen. 2021;861:503306. doi: 10.1016/j.mrgentox.2020.503306.", "ArticleIdList": ["10.1016/j.mrgentox.2020.503306", "33551100"]}, {"Citation": "Shebl F.M., Sakoda L.C., Black A., Koshiol J., Andriole G.L., Grubb R., Church T.R., Chia D., Zhou C., Chu L.W., et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: A PLCO study. Br. J. Cancer. 2012;107:207\u2013214. doi: 10.1038/bjc.2012.227.", "ArticleIdList": ["10.1038/bjc.2012.227", "PMC3389420", "22722313"]}, {"Citation": "Mahmud S.M., Franco E.L., Turner D., Platt R.W., Beck P., Skarsgard D., Tonita J., Sharpe C., Aprikian A.G. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: A population-based nested case-control study. PLoS ONE. 2011;6:e16412. doi: 10.1371/journal.pone.0016412.", "ArticleIdList": ["10.1371/journal.pone.0016412", "PMC3030588", "21297996"]}, {"Citation": "Espinosa-Cano E., Huerta-Madronal M., Camara-Sanchez P., Seras-Franzoso J., Schwartz S., Jr., Abasolo I., San Rom\u00e1n J., Aguilar M.R. Hyaluronic acid (HA)-coated naproxen-nanoparticles selectively target breast cancer stem cells through COX-independent pathways. Mater. Sci. Eng. C. 2021;124:112024. doi: 10.1016/j.msec.2021.112024.", "ArticleIdList": ["10.1016/j.msec.2021.112024", "33947532"]}, {"Citation": "Mohammed A., Janakiram N.B., Madka V., Zhang Y., Singh A., Biddick L., Li Q., Lightfoot S., Steele V.E., Lubet R.A., et al. Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive CarcinomaAspirin and Naproxen Dosing Regimens for Prevention of CRC. Cancer Prev. Res. 2019;12:751\u2013762. doi: 10.1158/1940-6207.CAPR-19-0312.", "ArticleIdList": ["10.1158/1940-6207.CAPR-19-0312", "PMC6849393", "31530543"]}, {"Citation": "Suh N., Reddy B.S., DeCastro A., Paul S., Lee H.J., Smolarek A.K., So J.Y., Simi B., Wang C.X., Janakiram N.B., et al. Combination of Atorvastatin with Sulindac or Naproxen Profoundly Inhibits Colonic Adenocarcinomas by Suppressing the p65/\u03b2-Catenin/Cyclin D1 Signaling Pathway in RatsAtorvastatin, with Sulindac or Naproxen, Inhibits Colon Cancer. Cancer Prev. Res. 2011;4:1895\u20131902. doi: 10.1158/1940-6207.CAPR-11-0222.", "ArticleIdList": ["10.1158/1940-6207.CAPR-11-0222", "PMC3208056", "21764859"]}, {"Citation": "Kim M.S., Kim J.E., Lim D.Y., Huang Z., Chen H., Langfald A., Lubet R.A., Grubbs C.J., Dong Z., Bode A.M. Naproxen Induces Cell-Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting PI3KNaproxen Targets PI3K to Prevent Urinary Bladder Cancer. Cancer Prev. Res. 2014;7:236\u2013245. doi: 10.1158/1940-6207.CAPR-13-0288.", "ArticleIdList": ["10.1158/1940-6207.CAPR-13-0288", "PMC3936888", "24327721"]}, {"Citation": "Zrieki A., Farinotti R., Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 2008;25:1991\u20132001. doi: 10.1007/s11095-008-9596-1.", "ArticleIdList": ["10.1007/s11095-008-9596-1", "18581209"]}, {"Citation": "Mohammed A., Yarla N.S., Madka V., Rao C.V. Clinically relevant anti-inflammatory agents for chemoprevention of colorectal cancer: New perspectives. Int. J. Mol. Sci. 2018;19:2332. doi: 10.3390/ijms19082332.", "ArticleIdList": ["10.3390/ijms19082332", "PMC6121559", "30096840"]}, {"Citation": "Chattopadhyay M., Kodela R., Nath N., Dastagirzada Y.M., Vel\u00e1zquez-Mart\u00ednez C.A., Boring D., Kashfi K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect. Biochem. Pharmacol. 2012;83:715\u2013722. doi: 10.1016/j.bcp.2011.12.018.", "ArticleIdList": ["10.1016/j.bcp.2011.12.018", "22222427"]}, {"Citation": "Quann E.J., Khwaja F., Zavitz K.H., Djakiew D. The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007;67:3254\u20133262. doi: 10.1158/0008-5472.CAN-06-3657.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-3657", "17409433"]}, {"Citation": "Adeniji A., Uddin J., Zang T., Tamae D., Wangtrakuldee P., Marnett L.J., Penning T.M. Discovery of (R)-2-(6-methoxynaphthalen-2-yl) butanoic acid as a potent and selective aldo-keto reductase 1C3 inhibitor. J. Med. Chem. 2016;59:7431\u20137444. doi: 10.1021/acs.jmedchem.6b00160.", "ArticleIdList": ["10.1021/acs.jmedchem.6b00160", "PMC5149398", "27486833"]}, {"Citation": "Flanagan J.U., Yosaatmadja Y., Teague R.M., Chai M.Z., Turnbull A.P., Squire C.J. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3. PLoS ONE. 2012;7:e43965. doi: 10.1371/journal.pone.0043965.", "ArticleIdList": ["10.1371/journal.pone.0043965", "PMC3429426", "22937138"]}, {"Citation": "Yellepeddi V.K., Radhakrishnan J., Radhakrishnan R. Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue. Prostate. 2018;78:80\u201385. doi: 10.1002/pros.23447.", "ArticleIdList": ["10.1002/pros.23447", "29105796"]}, {"Citation": "Krishnan A.V., Srinivas S., Feldman D. Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermato-Endocrinology. 2009;1:7\u201311. doi: 10.4161/derm.1.1.7106.", "ArticleIdList": ["10.4161/derm.1.1.7106", "PMC2715203", "20046582"]}, {"Citation": "Srinivas S., Feldman D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer. Res. 2009;29:3605\u20133610.", "ArticleIdList": ["19667155"]}, {"Citation": "Brasky T.M., Velicer C.M., Kristal A.R., Peters U., Potter J.D., White E. Nonsteroidal Anti-Inflammatory Drugs and Prostate Cancer Risk in the VITamins and Lifestyle (VITAL) CohortNSAIDs and Prostate Cancer Risk in VITAL. Cancer Epidemiol. Biomark. Prev. 2010;19:3185\u20133188. doi: 10.1158/1055-9965.EPI-10-0942.", "ArticleIdList": ["10.1158/1055-9965.EPI-10-0942", "PMC3005534", "20935064"]}, {"Citation": "Pantziarka P., Sukhatme V., Bouche G., Meheus L., Sukhatme V.P. Repurposing Drugs in Oncology (ReDO)\u2014Diclofenac as an anti-cancer agent. Ecancermedicalscience. 2016;10:610. doi: 10.3332/ecancer.2016.610.", "ArticleIdList": ["10.3332/ecancer.2016.610", "PMC4720497", "26823679"]}, {"Citation": "Barden J., Edwards J., Moore R., McQuay H. Single dose oral diclofenac for postoperative pain. Cochrane Database Syst. Rev. 2004:CD004768. doi: 10.1002/14651858.cd004768.", "ArticleIdList": ["10.1002/14651858.cd004768", "15106260"]}, {"Citation": "Johnsen J.I., Lindskog M., Ponthan F., Pettersen I., Elfman L., Orrego A., Sveinbj\u00f6rnsson B., Kogner P. NSAIDs in neuroblastoma therapy. Cancer Lett. 2005;228:195\u2013201. doi: 10.1016/j.canlet.2005.01.058.", "ArticleIdList": ["10.1016/j.canlet.2005.01.058", "15975708"]}, {"Citation": "Lanas A. Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: A trip from peptic ulcer to colon cancer. Am. J. Med. Sci. 2009;338:96\u2013106. doi: 10.1097/MAJ.0b013e3181ad8cd3.", "ArticleIdList": ["10.1097/MAJ.0b013e3181ad8cd3", "19680014"]}, {"Citation": "Valle B.L., D\u2019Souza T., Becker K.G., Wood W.H., III, Zhang Y., Wersto R.P., Morin P.J. Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS ONE. 2013;8:e61836. doi: 10.1371/journal.pone.0061836.", "ArticleIdList": ["10.1371/journal.pone.0061836", "PMC3634839", "23637916"]}, {"Citation": "Mayorek N., Naftali-Shani N., Grunewald M. Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PLoS ONE. 2010;5:e12715. doi: 10.1371/journal.pone.0012715.", "ArticleIdList": ["10.1371/journal.pone.0012715", "PMC2939880", "20856806"]}, {"Citation": "Lea M.A., Sura M., Desbordes C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer. Res. 2004;24:2765\u20132772.", "ArticleIdList": ["15517883"]}, {"Citation": "Adamson D.J., Frew D., Tatoud R., Wolf C.R., Palmer C.N. Diclofenac antagonizes peroxisome proliferator-activated receptor-\u03b3 signaling. Mol. Pharmacol. 2002;61:7\u201312. doi: 10.1124/mol.61.1.7.", "ArticleIdList": ["10.1124/mol.61.1.7", "11752200"]}, {"Citation": "Madrigal-Mart\u00ednez A., Const\u00e2ncio V., Lucio-Caza\u00f1a F.J., Fern\u00e1ndez-Mart\u00ednez A.B. PROSTAGLANDIN E2 stimulates cancer-related phenotypes in prostate cancer PC3 cells through cyclooxygenase-2. J. Cell. Physiol. 2019;234:7548\u20137559. doi: 10.1002/jcp.27515.", "ArticleIdList": ["10.1002/jcp.27515", "30367494"]}, {"Citation": "Gottfried E., Lang S.A., Renner K., Bosserhoff A., Gronwald W., Rehli M., Einhell S., Gedig I., Singer K., Seilbeck A., et al. New aspects of an old drug\u2013diclofenac targets MYC and glucose metabolism in tumor cells. PLoS ONE. 2013;8:e66987. doi: 10.1371/journal.pone.0066987.", "ArticleIdList": ["10.1371/journal.pone.0066987", "PMC3706586", "23874405"]}, {"Citation": "Inoue T., Anai S., Onishi S., Miyake M., Tanaka N., Hirayama A., Fujimoto K., Hirao Y. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol. 2013;13:1. doi: 10.1186/1471-2490-13-1.", "ArticleIdList": ["10.1186/1471-2490-13-1", "PMC3561196", "23289871"]}, {"Citation": "Gebril S.M., Ito Y., Shibata M., Maemura K., Abu-Dief E.E., Hussein M.R.A., Abdelaal U.M., Elsayed H.M., Otsuki Y., Higuchi K. Indomethacin can induce cell death in rat gastric parietal cells through alteration of some apoptosis-and autophagy-associated molecules. Int. J. Exp. Pathol. 2020;101:230\u2013247. doi: 10.1111/iep.12370.", "ArticleIdList": ["10.1111/iep.12370", "PMC7691216", "32985762"]}, {"Citation": "Sun S.-Q., Gu X., Gao X.-S., Li Y., Yu H., Xiong W., Yu H., Wang W., Li Y., Teng Y., et al. Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation. Oncotarget. 2020;7:48050. doi: 10.18632/oncotarget.10347. Erratum in Oncotarget 2020, 11, 1575.", "ArticleIdList": ["10.18632/oncotarget.10347", "PMC5216999", "27385003"]}, {"Citation": "Liu C., Lou W., Zhu Y., Yang J.C., Nadiminty N., Gaikwad N.W., Evans C.P., Gao A.C. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015;75:1413\u20131422. doi: 10.1158/0008-5472.CAN-14-3080.", "ArticleIdList": ["10.1158/0008-5472.CAN-14-3080", "PMC4383695", "25649766"]}, {"Citation": "Hamid A.R.A.H., Pfeiffer M.J., Verhaegh G.W., Schaafsma E., Brandt A., Sweep F.C.G.J., Sedelaar J.P.M., Schalken J.A. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol. Med. 2012;18:1449\u20131455. doi: 10.2119/molmed.2012.00296.", "ArticleIdList": ["10.2119/molmed.2012.00296", "PMC3563708", "23196782"]}, {"Citation": "Liedtke A.J., Adeniji A.O., Chen M., Byrns M.C., Jin Y., Christianson D.W., Marnett L.J., Penning T.M. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. J. Med. Chem. 2013;56:2429\u20132446. doi: 10.1021/jm3017656.", "ArticleIdList": ["10.1021/jm3017656", "PMC3638264", "23432095"]}, {"Citation": "Cai C., Chen S., Ng P., Bubley G.J., Nelson P.S., Mostaghel E.A., Marck B., Matsumoto A.M., Simon N.I., Wang H., et al. Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 InhibitorsProstate Cancer Resistance to CYP17A1 Inhibitors. Cancer Res. 2011;71:6503\u20136513. doi: 10.1158/0008-5472.CAN-11-0532.", "ArticleIdList": ["10.1158/0008-5472.CAN-11-0532", "PMC3209585", "21868758"]}, {"Citation": "Liu C., Yang J.C., Armstrong C.M., Lou W., Liu L., Qiu X., Zou B., Lombard A.P., D\u2019Abronzo L.S., Evans C.P., et al. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate CancerAKR1C3 Regulates AR-V7 and Confers Resistance. Mol. Cancer Ther. 2019;18:1875\u20131886. doi: 10.1158/1535-7163.MCT-18-1322.", "ArticleIdList": ["10.1158/1535-7163.MCT-18-1322", "PMC6995728", "31308078"]}, {"Citation": "Cimolai N. The potential and promise of mefenamic acid. Expert Rev. Clin. Pharmacol. 2013;6:289\u2013305. doi: 10.1586/ecp.13.15.", "ArticleIdList": ["10.1586/ecp.13.15", "23656341"]}, {"Citation": "Armagan G., Turunc E., Kanit L., Yalcin A. Neuroprotection by mefenamic acid against D-serine: Involvement of oxidative stress, inflammation and apoptosis. Free. Radic. Res. 2012;46:726\u2013739. doi: 10.3109/10715762.2012.669836.", "ArticleIdList": ["10.3109/10715762.2012.669836", "22369458"]}, {"Citation": "Asanuma M., Nishibayashi-Asanuma S., Miyazaki I., Kohno M., Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J. Neurochem. 2001;76:1895\u20131904. doi: 10.1046/j.1471-4159.2001.00205.x.", "ArticleIdList": ["10.1046/j.1471-4159.2001.00205.x", "11259508"]}, {"Citation": "Patel S.S., Tripathi R., Chavda V.K., Savjani J.K. Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property. Anticancer Agents Med. Chem. 2020;20:998\u20131008. doi: 10.2174/1871520620666200415100614.", "ArticleIdList": ["10.2174/1871520620666200415100614", "32294047"]}, {"Citation": "Hosseinimehr S.J., Nobakht R., Ghasemi A., Pourfallah T.A. Radioprotective effect of mefenamic acid against radiation-induced genotoxicity in human lymphocytes. Radiat. Oncol. J. 2015;33:256. doi: 10.3857/roj.2015.33.3.256.", "ArticleIdList": ["10.3857/roj.2015.33.3.256", "PMC4607580", "26484310"]}, {"Citation": "Seyyedi R., Amiri F.T., Farzipour S., Mihandoust E., Hosseinimehr S.J. Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice. Med. Oncol. 2022;39:18. doi: 10.1007/s12032-021-01618-3.", "ArticleIdList": ["10.1007/s12032-021-01618-3", "34982268"]}, {"Citation": "\u010ceponyt\u0117 U., Pa\u0161kevi\u010di\u016bt\u0117 M., Petrikait\u0117 V. Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures. Cancer Manag. Res. 2018;10:1543. doi: 10.2147/CMAR.S163747.", "ArticleIdList": ["10.2147/CMAR.S163747", "PMC6007190", "29942156"]}, {"Citation": "Woo D.H., Han I.-S., Jung G. Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway. Life Sci. 2004;75:2439\u20132449. doi: 10.1016/j.lfs.2004.04.042.", "ArticleIdList": ["10.1016/j.lfs.2004.04.042", "15350819"]}, {"Citation": "Soriano-Hern\u00e1ndez A.D., Galvan-Salazar H.R., Montes-Galindo D.A., Rodriguez-Hernandez A., Martinez-Martinez R., Guzman-Esquivel J., Valdez-Velazquez L.L., Baltazar-Rodriguez L.M., Espinoza-G\u00f3mez F., Rojas-Martinez A., et al. Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: A preclinical evaluation. Int. Urol. Nephrol. 2012;44:471\u2013477. doi: 10.1007/s11255-011-0012-0.", "ArticleIdList": ["10.1007/s11255-011-0012-0", "21660425"]}, {"Citation": "Melnikov V., Tiburcio-Jimenez D., A Mendoza-Hernandez M., Delgado-Enciso J., De-Leon-Zaragoza L., Guzman-Esquivel J., Rodriguez-Sanchez I.P., Martinez-Fierro M.L., Lara-Esqueda A., Delgado-Enciso O.G., et al. Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: Additional beneficial effect found in a controlled clinical trial for prostate cancer therapy. Am. J. Transl. Res. 2021;13:4535.", "ArticleIdList": ["PMC8205720", "34150033"]}, {"Citation": "Guzman-Esquivel J., Mendoza-Hernandez M.A., Tiburcio-Jimenez D., Avila-Zamora O.N., Delgado-Enciso J., De-Leon-Zaragoza L., Casarez-Price J.C., Rodriguez-Sanchez I.P., Martinez-Fierro M.L., Meza-Robles C., et al. Decreased biochemical progression in patients with castration-resistant prostate cancer using a novel mefenamic acid anti-inflammatory therapy: A randomized controlled trial. Oncol. Lett. 2020;19:4151\u20134160. doi: 10.3892/ol.2020.11509.", "ArticleIdList": ["10.3892/ol.2020.11509", "PMC7204620", "32391109"]}, {"Citation": "Buskbjerg C.R., Amidi A., Buus S., Gravholt C.H., Hadi Hosseini S., Zachariae R. Androgen deprivation therapy and cognitive decline\u2014Associations with brain connectomes, endocrine status, and risk genotypes. Prostate Cancer Prostatic Dis. 2022;25:208\u2013218. doi: 10.1038/s41391-021-00398-1.", "ArticleIdList": ["10.1038/s41391-021-00398-1", "34088994"]}, {"Citation": "Qui\u00f1ones O.G., Pierre M.B. Cutaneous application of celecoxib for inflammatory and cancer diseases. Curr. Cancer Drug Targets. 2019;19:5\u201316. doi: 10.2174/1568009618666180430125201.", "ArticleIdList": ["10.2174/1568009618666180430125201", "29714143"]}, {"Citation": "To\u0142oczko-Iwaniuk N., Dziemia\u0144czyk-Pakie\u0142a D., Nowaszewska B.K., Celi\u0144ska-Janowicz K., Miltyk W. Celecoxib in cancer therapy and prevention\u2013review. Curr. Drug Targets. 2019;20:302\u2013315. doi: 10.2174/1389450119666180803121737.", "ArticleIdList": ["10.2174/1389450119666180803121737", "30073924"]}, {"Citation": "Benson P., Yudd M., Sims D., Chang V., Srinivas S., Kasimis B. Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma. Clin. Nephrol. 2012;78:376\u2013381. doi: 10.5414/CN107168.", "ArticleIdList": ["10.5414/CN107168", "22735362"]}, {"Citation": "Atari-Hajipirloo S., Nikanfar S., Heydari A., Kheradmand F. Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells. Res. Pharm. Sci. 2017;12:67\u201373.", "ArticleIdList": ["PMC5333482", "28255316"]}, {"Citation": "Atari-Hajipirloo S., Nikanfar S., Heydari A., Noori F., Kheradmand F. The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-\u03baB genes expression. Cell. Mol. Biol. 2016;62:68\u201374.", "ArticleIdList": ["26950454"]}, {"Citation": "Mohammadian M., Zeynali S., Azarbaijani A.F., Ansari M.H.K., Kheradmand F. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. Res. Pharm. Sci. 2017;12:517.", "ArticleIdList": ["PMC5691578", "29204180"]}, {"Citation": "Nikanfar S., Atari-Hajipirloo S., Kheradmand F., Rashedi J., Heydari A. Cytotoxic effect of 2, 5-dimethyl-celecoxib as a structural analog of celecoxib on human colorectal cancer (HT-29) cell line. Cell. Mol. Biol. 2018;64:8\u201313. doi: 10.14715/cmb/2018.64.7.2.", "ArticleIdList": ["10.14715/cmb/2018.64.7.2", "29974839"]}, {"Citation": "Nikanfar S., ATARI-HAJIPIRLOO S., KHERADMAND F., HEYDARI A. Imatinib Synergizes with 2, 5-Dimethylcelecoxib, a Close Derivative of Celecoxib, in HT-29 Colorectal Cancer Cells: Involvement of Vascular Endothelial Growth Factor. J. Res. Pharm. 2023;27:948\u2013956."}, {"Citation": "Zielinski S.L. Despite positive studies, popularity of chemoprevention drugs increasing slowly. J. Natl. Cancer Inst. 2004;96:1410\u20131412. doi: 10.1093/jnci/96.19.1410.", "ArticleIdList": ["10.1093/jnci/96.19.1410", "15467023"]}, {"Citation": "Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000;342:1946\u20131952. doi: 10.1056/NEJM200006293422603.", "ArticleIdList": ["10.1056/NEJM200006293422603", "10874062"]}, {"Citation": "Henney J.E. Celecoxib indicated for FAP. JAMA. 2000;283:1131. doi: 10.1001/jama.283.9.1131-JFD00001-2-1.", "ArticleIdList": ["10.1001/jama.283.9.1131-JFD00001-2-1", "0"]}, {"Citation": "Smith M.R., Manola J., Kaufman D.S., Oh W.K., Bubley G.J., Kantoff P.W. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J. Clin. Oncol. 2006;24:2723\u20132728. doi: 10.1200/JCO.2005.03.7804.", "ArticleIdList": ["10.1200/JCO.2005.03.7804", "16782912"]}, {"Citation": "Brizzolara A., Benelli R., Ven\u00e8 R., Barboro P., Poggi A., Tosetti F., Ferrari N. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. Cancer Lett. 2017;400:9\u201317. doi: 10.1016/j.canlet.2017.04.025.", "ArticleIdList": ["10.1016/j.canlet.2017.04.025", "28450158"]}, {"Citation": "Kypta R.M., Waxman J. Wnt/\u03b2-catenin signalling in prostate cancer. Nat. Rev. Urol. 2012;9:418\u2013428. doi: 10.1038/nrurol.2012.116.", "ArticleIdList": ["10.1038/nrurol.2012.116", "22710668"]}, {"Citation": "Egashira I., Takahashi-Yanaga F., Nishida R., Arioka M., Igawa K., Tomooka K., Nakatsu Y., Tsuzuki T., Nakabeppu Y., Kitazono T., et al. Celecoxib and 2, 5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/\u03b2-catenin signaling pathway. Cancer Sci. 2017;108:108\u2013115. doi: 10.1111/cas.13106.", "ArticleIdList": ["10.1111/cas.13106", "PMC5276826", "27761963"]}, {"Citation": "Lin J.Z., Hameed I., Xu Z., Yu Y., Ren Z.Y., Zhu J.G. Efficacy of gefitinib-celecoxib combination therapy in docetaxel-resistant prostate cancer. Oncol. Rep. 2018;40:2242\u20132250. doi: 10.3892/or.2018.6595.", "ArticleIdList": ["10.3892/or.2018.6595", "30066906"]}, {"Citation": "Dandekar D.S., Lopez M., Carey R.I., Lokeshwar B.L. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and-9 in prostate cancer cells. Int. J. Cancer. 2005;115:484\u2013492. doi: 10.1002/ijc.20878.", "ArticleIdList": ["10.1002/ijc.20878", "15688368"]}, {"Citation": "Wang J.-L., Lin K.-L., Chou C.-T., Kuo C.-C., Cheng J.-S., Hsu S.-S., Chang H.-T., Tsai J.-Y., Liao W.-C., Lu Y.-C., et al. Effect of celecoxib on Ca2+ handling and viability in human prostate cancer cells (PC3) Drug Chem. Toxicol. 2012;35:456\u2013462. doi: 10.3109/01480545.2011.638927.", "ArticleIdList": ["10.3109/01480545.2011.638927", "22168270"]}, {"Citation": "Johnson A.J., Hsu A.-L., Chen C.-S. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv. Enzym. Regul. 2001;1:221\u2013235. doi: 10.1016/S0065-2571(00)00015-7.", "ArticleIdList": ["10.1016/S0065-2571(00)00015-7", "11384747"]}, {"Citation": "Johnson A.J., Hsu A.-L., Lin H.-P., Song X., Chen C.-S. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: A plausible link with its anti-tumour effect and cardiovascular risks. Biochem. J. 2002;366:831\u2013837. doi: 10.1042/bj20020279.", "ArticleIdList": ["10.1042/bj20020279", "PMC1222837", "12076251"]}, {"Citation": "Hsu A.-L., Ching T.-T., Wang D.-S., Song X., Rangnekar V.M., Chen C.-S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 2000;275:11397\u201311403. doi: 10.1074/jbc.275.15.11397.", "ArticleIdList": ["10.1074/jbc.275.15.11397", "10753955"]}, {"Citation": "Zheng X., Cui X.-X., Avila G.E., Huang M.-T., Liu Y., Patel J., Kong A.N.T., Paulino R., Shih W.J., Lin Y., et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin. Cancer Res. 2007;13:5480\u20135487. doi: 10.1158/1078-0432.CCR-07-0242.", "ArticleIdList": ["10.1158/1078-0432.CCR-07-0242", "17875778"]}, {"Citation": "Yerokun T., Winfield L.L. LLW-3-6 and celecoxib impacts growth in prostate cancer cells and subcellular localization of COX-2. Anticancer. Res. 2014;34:4755\u20134759.", "ArticleIdList": ["PMC4204802", "25202054"]}, {"Citation": "Garcia M., Velez R., Romagosa C., Majem B., Pedrola N., Olivan M., Rigau M., Guiu M., Gomis R.R., Morote J., et al. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int. 2014;113:E164\u2013E177. doi: 10.1111/bju.12503.", "ArticleIdList": ["10.1111/bju.12503", "24127882"]}, {"Citation": "Ko C.J., Lan S.W., Lu Y.C., Cheng T.S., Lai P.F., Tsai C.H., Hsu T.W., Lin H.Y., Shyu H.Y., Wu S.R., et al. Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. Oncogene. 2017;36:4597\u20134609. doi: 10.1038/onc.2017.82.", "ArticleIdList": ["10.1038/onc.2017.82", "28368394"]}, {"Citation": "Benelli R., Barboro P., Costa D., Astigiano S., Barbieri O., Capaia M., Poggi A., Ferrari N. Multifocal signal modulation therapy by celecoxib: A strategy for managing castration-resistant prostate cancer. Int. J. Mol. Sci. 2019;20:6091. doi: 10.3390/ijms20236091.", "ArticleIdList": ["10.3390/ijms20236091", "PMC6929142", "31816863"]}, {"Citation": "Narayanan N.K., Narayanan B.A., Reddy B.S. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-\u03baB, and steroid hormone receptors. Int. J. Oncol. 2005;26:785\u2013792. doi: 10.3892/ijo.26.3.785.", "ArticleIdList": ["10.3892/ijo.26.3.785", "15703837"]}, {"Citation": "Zheng X., Cui X.X., Gao Z., Zhao Y., Lin Y., Shih W.J., Huang M.T., Liu Y., Rabson A., Reddy B., et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev. Res. 2010;3:114\u2013124. doi: 10.1158/1940-6207.CAPR-09-0059.", "ArticleIdList": ["10.1158/1940-6207.CAPR-09-0059", "PMC2803700", "20051379"]}, {"Citation": "Huang H., Cui X.-X., Chen S., Goodin S., Liu Y., He Y., Li D., Wang H., Van Doren J., Dipaola R.S., et al. Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo. Anticancer. Res. 2014;34:3357\u20133363.", "ArticleIdList": ["PMC5249253", "24982340"]}, {"Citation": "Katkoori V., Manne K., Vital-Reyes V., Rodr\u00edguez-Burford C., Shanmugam C., Sthanam M., Manne U., Chatla C., Abdulkadir S., Grizzle W. Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotech. Histochem. 2013;88:38\u201346. doi: 10.3109/10520295.2012.724713.", "ArticleIdList": ["10.3109/10520295.2012.724713", "23167625"]}, {"Citation": "Wang H., Cui X.-X., Goodin S., Ding N., Van Doren J., Du Z., Huang M.-T., Liu Y., Cheng X., Dipaola R.S., et al. Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib. Oncol. Rep. 2014;31:835\u2013841. doi: 10.3892/or.2013.2885.", "ArticleIdList": ["10.3892/or.2013.2885", "PMC3981114", "24296978"]}, {"Citation": "Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., Shiraishi F., Taba Y., Miwa Y., Morimoto S., Iida M., Sasaguri T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem. Pharmacol. 2007;73:1318\u20131329. doi: 10.1016/j.bcp.2006.12.033.", "ArticleIdList": ["10.1016/j.bcp.2006.12.033", "17270149"]}, {"Citation": "Tian J., Guo F., Chen Y., Li Y., Yu B., Li Y. Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation. Cancer Lett. 2019;448:1\u201310. doi: 10.1016/j.canlet.2019.01.002.", "ArticleIdList": ["10.1016/j.canlet.2019.01.002", "30673592"]}, {"Citation": "Hassani S., Maghsoudi H., Fattahi F., Malekinejad F., Hajmalek N., Sheikhnia F., Kheradmand F., Fahimirad S., Ghorbanpour M. Flavonoids nanostructures promising therapeutic efficiencies in colorectal cancer. Int. J. Biol. Macromol. 2023;241:124508. doi: 10.1016/j.ijbiomac.2023.124508.", "ArticleIdList": ["10.1016/j.ijbiomac.2023.124508", "37085076"]}, {"Citation": "Patel M.I., Subbaramaiah K., Du B., Chang M., Yang P., Newman R.A., Cordon-Cardo C., Thaler H.T., Dannenberg A.J. Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res. 2005;11:1999\u20132007. doi: 10.1158/1078-0432.CCR-04-1877.", "ArticleIdList": ["10.1158/1078-0432.CCR-04-1877", "15756026"]}, {"Citation": "Hayashi T., Fujita K., Nojima S., Hayashi Y., Nakano K., Ishizuya Y., Wang C., Yamamoto Y., Kinouchi T., Matsuzaki K., et al. High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 SignalingHFD-Induced Inflammation and Prostate Cancer Growth. Clin. Cancer Res. 2018;24:4309\u20134318. doi: 10.1158/1078-0432.CCR-18-0106.", "ArticleIdList": ["10.1158/1078-0432.CCR-18-0106", "29776955"]}, {"Citation": "Kido L.A., Montico F., Vendramini-Costa D.B., Pilli R.A., Cagnon V.H.A. Goniothalamin and celecoxib effects during aging: Targeting pro-inflammatory mediators in chemoprevention of prostatic disorders. Prostate. 2017;77:838\u2013848. doi: 10.1002/pros.23324.", "ArticleIdList": ["10.1002/pros.23324", "28191652"]}, {"Citation": "Narayanan N.K., Nargi D., Horton L., Reddy B.S., Bosland M.C., Narayanan B.A. Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: Preventive effects of celecoxib. Prostate. 2009;69:133\u2013141. doi: 10.1002/pros.20862.", "ArticleIdList": ["10.1002/pros.20862", "18819100"]}, {"Citation": "Silva R.S., Kido L.A., Montico F., Vendramini-Costa D.B., Pilli R.A., Cagnon V.H.A. Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice. Cell Biol. Int. 2018;42:1006\u20131020. doi: 10.1002/cbin.10967.", "ArticleIdList": ["10.1002/cbin.10967", "29603508"]}, {"Citation": "Kido L.A., Montico F., Sauce R., Macedo A.B., Minatel E., Costa D.B.V., de Carvalho J.E., Pilli R.A., Cagnon V.H.A. Anti-inflammatory therapies in TRAMP mice: Delay in PCa progression. Endocr. -Relat. Cancer. 2016;23:235\u2013250. doi: 10.1530/ERC-15-0540.", "ArticleIdList": ["10.1530/ERC-15-0540", "26772819"]}, {"Citation": "Narayanan B.A., Narayanan N.K., Pittman B., Reddy B.S. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. 2004;10:7727\u20137737. doi: 10.1158/1078-0432.CCR-04-0732.", "ArticleIdList": ["10.1158/1078-0432.CCR-04-0732", "15570007"]}, {"Citation": "Gupta S., Adhami V.M., Subbarayan M., MacLennan G.T., Lewin J.S., Hafeli U.O., Fu P., Mukhtar H. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2004;64:3334\u20133343. doi: 10.1158/0008-5472.CAN-03-2422.", "ArticleIdList": ["10.1158/0008-5472.CAN-03-2422", "15126378"]}, {"Citation": "Narayanan B.A., Narayanan N.K., Pttman B., Reddy B.S. Adenocarcina of the mouse prostate growth inhibition by celecoxib: Downregulation of transcription factors involved in COX-2 inhibition. Prostate. 2006;66:257\u2013265. doi: 10.1002/pros.20331.", "ArticleIdList": ["10.1002/pros.20331", "16175586"]}, {"Citation": "Mateus P.A.M., Kido L.A., Silva R.S., Cagnon V.H.A., Montico F. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice. Prostate. 2019;79:515\u2013535. doi: 10.1002/pros.23758.", "ArticleIdList": ["10.1002/pros.23758", "30585351"]}, {"Citation": "Adhami V.M., Malik A., Zaman N., Sarfaraz S., Siddiqui I.A., Syed D.N., Afaq F., Pasha F.S., Saleem M., Mukhtar H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 2007;13:1611\u20131619. doi: 10.1158/1078-0432.CCR-06-2269.", "ArticleIdList": ["10.1158/1078-0432.CCR-06-2269", "17332308"]}, {"Citation": "Ho V.W., Hamilton M.J., Dang N.-H.T., Hsu B.E., Adomat H.H., Guns E.S., Weljie A., Samudio I., Bennewith K.L., Krystal G. A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. Carcinogenesis. 2014;35:2291\u20132299. doi: 10.1093/carcin/bgu147.", "ArticleIdList": ["10.1093/carcin/bgu147", "PMC4178469", "25023988"]}, {"Citation": "Abedinpour P., Baron V.T., Welsh J., Borgstr\u00f6m P. Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. Prostate. 2011;71:813\u2013823. doi: 10.1002/pros.21297.", "ArticleIdList": ["10.1002/pros.21297", "PMC3139688", "21456064"]}, {"Citation": "Wang C., Chen J., Zhang Q., Li W., Zhang S., Xu Y., Wang F., Zhang B., Zhang Y., Gao W.Q. Elimination of CD4lowHLA-G+ T cells overcomes castration-resistance in prostate cancer therapy. Cell Res. 2018;28:1103\u20131117. doi: 10.1038/s41422-018-0089-4.", "ArticleIdList": ["10.1038/s41422-018-0089-4", "PMC6218442", "30297869"]}, {"Citation": "Pruthi R.S., Derksen J.E., Moore D., Carson C.C., Grigson G., Watkins C., Wallen E. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin. Cancer Res. 2006;12:2172\u20132177. doi: 10.1158/1078-0432.CCR-05-2067.", "ArticleIdList": ["10.1158/1078-0432.CCR-05-2067", "16609031"]}, {"Citation": "Pruthi R., Derksen J., Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int. 2004;93:275\u2013278. doi: 10.1111/j.1464-410X.2004.04601.x.", "ArticleIdList": ["10.1111/j.1464-410X.2004.04601.x", "14764122"]}, {"Citation": "Ganswindt U., Budach W., Jendrossek V., Becker G., Bamberg M., Belka C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer\u2013a phase I study. Radiat. Oncol. 2006;1:9. doi: 10.1186/1748-717X-1-9.", "ArticleIdList": ["10.1186/1748-717X-1-9", "PMC1464385", "16722607"]}, {"Citation": "Sooriakumaran P., Macanas-Pirard P., Bucca G., Henderson A., Langley S.E.M., Laing R.W., Smith C.P., E Laing E., Coley H.M. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. Cancer Genom. Proteom. 2009;6:93\u201399.", "ArticleIdList": ["19451093"]}, {"Citation": "Flamiatos J.F., Beer T.M., Graff J.N., Eilers K.M., Tian W., Sekhon H.S., Garzotto M. Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: Double-blind randomised study of pre-prostatectomy celecoxib or placebo. BJU Int. 2017;119:709\u2013716. doi: 10.1111/bju.13612.", "ArticleIdList": ["10.1111/bju.13612", "27480340"]}, {"Citation": "Kattan J., Bachour M., Farhat F., El Rassy E., Assi T., Ghosn M. Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. Investig. New Drugs. 2016;34:474\u2013480. doi: 10.1007/s10637-016-0357-4.", "ArticleIdList": ["10.1007/s10637-016-0357-4", "27159981"]}, {"Citation": "Sooriakumaran P., Coley H.M., Fox S.B., Macanas-Pirard P., Lovell D.P., Henderson A., Eden C.G., Miller P.D., Langley S.E.M., Laing R.W. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer. Res. 2009;29:1483\u20131488.", "ArticleIdList": ["19443354"]}, {"Citation": "Etheridge T., Liou J., Downs T.M., Abel E.J., Richards K.A., Jarrard D.F. The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. Am. J. Clin. Exp. Urol. 2018;6:123\u2013132.", "ArticleIdList": ["PMC6055075", "30038944"]}, {"Citation": "Landre T., Des Guetz G., Chouahnia K., Fossey-Diaz V., Taleb C., Culine S. Is there a benefit of addition docetaxel, abiraterone, celecoxib, or zoledronic acid in initial treatments for patients older than 70 years with hormone-sensitive advanced prostate cancer? A meta-analysis. Clin. Genitourin. Cancer. 2019;17:e806\u2013e813. doi: 10.1016/j.clgc.2019.05.001.", "ArticleIdList": ["10.1016/j.clgc.2019.05.001", "31227430"]}, {"Citation": "Carles J., Font A., Mellado B., Domenech M., Gallardo E., Gonz\u00e1lez-Larriba J.L., Catalan G., Alfaro J., del Alba A.G., Nogu\u00e9 M., et al. Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: Final results from a phase II study. Br. J. Cancer. 2007;97:1206\u20131210. doi: 10.1038/sj.bjc.6604030.", "ArticleIdList": ["10.1038/sj.bjc.6604030", "PMC2360463", "17955053"]}, {"Citation": "Albouy B., Tourani J.-M., Allain P., Rolland F., Staerman F., Eschwege P., Pfister C. Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer. BJU Int. 2007;100:770\u2013774. doi: 10.1111/j.1464-410X.2007.07095.x.", "ArticleIdList": ["10.1111/j.1464-410X.2007.07095.x", "17822458"]}, {"Citation": "Harirforoosh S., Asghar W., Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J. Pharm. Pharm. Sci. 2013;16:821\u2013847. doi: 10.18433/J3VW2F.", "ArticleIdList": ["10.18433/J3VW2F", "24393558"]}, {"Citation": "Fernandes D.C., Norman A.J. Drug-induced gastrointestinal disorders. Medicine. 2019;47:301\u2013308. doi: 10.1016/j.mpmed.2019.02.010.", "ArticleIdList": ["10.1016/j.mpmed.2019.02.010"]}, {"Citation": "Tai F.W.D., McAlindon M.E. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin. Med. 2021;21:131. doi: 10.7861/clinmed.2021-0039.", "ArticleIdList": ["10.7861/clinmed.2021-0039", "PMC8002800", "33762373"]}, {"Citation": "Masso Gonzalez E.L., Patrignani P., Tacconelli S., Rodr\u00edguez L.A.G. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62:1592\u20131601. doi: 10.1002/art.27412.", "ArticleIdList": ["10.1002/art.27412", "20178131"]}, {"Citation": "Antonucci R., Cuzzolin L., Arceri A., Dess\u00ec A., Fanos V. Changes in urinary PGE 2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur. J. Clin. Pharmacol. 2009;65:223\u2013230. doi: 10.1007/s00228-008-0586-3.", "ArticleIdList": ["10.1007/s00228-008-0586-3", "19048246"]}, {"Citation": "Horbach S.J., Lopes R.D., Guaragna J.C.D.C., Martini F., Mehta R.H., Petracco J.B., Bodanese L.C., Adauto Filho C., Cirenza C., de Paola A.A., et al. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: The NAFARM randomized trial. Am. J. Med. 2011;124:1036\u20131042. doi: 10.1016/j.amjmed.2011.07.026.", "ArticleIdList": ["10.1016/j.amjmed.2011.07.026", "22017782"]}, {"Citation": "Varga Z., rafay ali Sabzwari S., Vargova V., Sabzwari S.R.A. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: An under-recognized public health issue. Cureus. 2017;9:e1144. doi: 10.7759/cureus.1144.", "ArticleIdList": ["10.7759/cureus.1144", "PMC5422108", "28491485"]}, {"Citation": "Fanelli A., Ghisi D., Aprile P.L., Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: Latest evidence and clinical implications. Ther. Adv. Drug Saf. 2017;8:173\u2013182. doi: 10.1177/2042098617690485.", "ArticleIdList": ["10.1177/2042098617690485", "PMC5455842", "28607667"]}, {"Citation": "Vonkeman H.E., van de Laar M.A., editors. Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. Elsevier; Amsterdam, The Netherlands: 2010. Seminars in arthritis and rheumatism.", "ArticleIdList": ["18823646"]}, {"Citation": "Lanas A., Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: Benefits and risks of therapeutic strategies. Ann. Med. 2006;38:415\u2013428. doi: 10.1080/07853890600925843.", "ArticleIdList": ["10.1080/07853890600925843", "17008305"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "10", "Day": "20"}, {"Year": "2023", "Month": "11", "Day": "9"}, {"Year": "2023", "Month": "11", "Day": "13"}, {"Year": "2023", "Month": "11", "Day": "25", "Hour": "12", "Minute": "48"}, {"Year": "2023", "Month": "11", "Day": "25", "Hour": "12", "Minute": "47"}, {"Year": "2023", "Month": "11", "Day": "25", "Hour": "1", "Minute": "6"}, {"Year": "2023", "Month": "11", "Day": "16"}], "PublicationStatus": "epublish", "ArticleIdList": ["38001694", "PMC10670652", "10.3390/cancers15225435", "cancers15225435"]}}], "PubmedBookArticle": []}